Aurobindo Pharma Management Guidance Tracker

Management targets 18%+ EBITDA margin for FY24, excluding Revlimid contribution, supported by operating leverage and export benefit normalization.

Management targets full-year EBITDA margin above 20%, supported by gRevlimid launch and cost efficiencies.

Management reiterated confidence in achieving 20% EBITDA margin for FY24, supported by operational efficiencies and cost improvements.

Management expects EBITDA margin to improve to 21%-22% in FY25, driven by operating leverage and ramp-up of new capacities.

Management reiterated the internal EBITDA margin target of 21%-22% for FY25, with potential revision in Q2 call.

Management reiterated internal target for full-year EBITDA margin, implying H2 margins will be higher than H1.

Management reaffirmed achieving 21%-22% EBITDA margin for FY25, despite Q3 margin of 20.4%, citing stronger Q4 with increased transient sales and operational efficiencies.

The company internally aims to keep EBITDA margins at present levels (around 20.8%) for FY26.

Management reiterated internal target margin range of 20-21% for FY26, supported by volume expansion and new site ramp-up.

Management reiterated confidence in achieving internal margin target of 20-21% for FY26, driven by operational leverage and cost efficiency.

The OSG facility in China is on track to deliver EBITDA breakeven by Q3-Q4 FY26, with European approval for 10 products and 3 local approvals.

Management expects to achieve EBITDA margins on the higher side of 20-21% for FY2026, driven by Pen G ramp-up, injectable growth, and cost efficiencies.

Eugia aims to achieve $500M+ global revenue in FY24, up from $411M pro forma last year, excluding Revlimid.

On track to achieve $560 million globally for Eugia Specialities in FY24, driven by injectable growth.

The China oral solids plant has received cGMP approval and is expected to start generating revenue from Q1 or Q2 of FY2025.

Management guided Xolair biosimilar revenue potential of $120M-$180M by 2028, assuming approvals in US and Europe.

Eugia expects to maintain a global revenue run rate of $150 million per year, with US contributing $100-$110 million.

Europe formulations on track to achieve EUR 880 million+ for FY25, with potential to reach EUR 900 million.

Despite Q1/Q2 slowdown, management expects full-year injectable sales to be around $600M, with a possible 5% variance.

The China OSD plant (2B units capacity) commercialized in November 2024, expected to ramp up and contribute to revenues in FY26, initially supplying Europe.

Management expects revenue growth of 8-9% in FY26, excluding the contribution from transient products like Revlimid.

The China plant, commercialized in FY25, is expected to contribute revenues in FY26 and turn breakeven or slightly positive.

Management expects European formulations to exceed €1 billion in annual revenues by the end of FY26.

European business on track to comfortably surpass EUR 1 billion annual revenue milestone by end of FY26, driven by consistent growth across major markets.

The Dayton facility has transitioned to commercial phase and will begin contributing revenues significantly from FY2027 onwards.

PLI facilities and investments targeted to be completed before 1st April 2024, with full ramp-up expected by mid-FY25.

Pen-G plant expected to be operational by end of Q4 FY24 or early Q1 FY25, with 15,000-ton capacity.

First oncology biosimilar launch in India expected this year, with multiple launches in regulated markets from FY25 onwards.

Three biosimilars (pegfilgrastim, filgrastim, trastuzumab) to be filed in Europe by end of January 2024.

Pen-G and 6-APA facilities will start meaningful contribution from Q3 FY25, with full ramp-up expected by September 2024.

Pen-G plant expected to ramp up significantly from October 2024, with 80% capacity utilization targeted by Q3.

Expect to achieve breakeven at the penicillin G facility by Q4 FY25, with positive contribution from FY26.

Phase III recruitment completed; filing expected in 2025 with commercialization in Europe in 2026.

Following positive CHMP opinions, Filgrastim and Pegfilgrastim expected to launch in EU in Q2 FY26, with revenue bookings starting from that quarter.

The China facility, with initial capacity of 2 billion+ units, is expected to break even at EBITDA level by Q3 FY26.

The PNG plant resumed operations and is expected to generate healthy EBITDA from Q3 onwards as yields improve.

Marketing authorization application for denosumab biosimilar to be submitted to EMA in April 2026; FDA submission expected in July quarter of 2026.

Based on current production levels, the company expects to produce more than 10,000 metric tons on an annualized basis over the next 12 months.

Non-aseptic lines expected to restart by end of February 2024; aseptic lines within 1-2 months; full production by end of FY24.

Trastuzumab biosimilar to be filed with US FDA within the next 3 months, following a successful Type 4 pre-submission meeting.

China plant expected to start commercial production from Q3 FY25, with ramp-up from Q4 FY25.

The US-based OSD plant at Dayton is expected to be commercialized in FY26, adding capacity for the US market.

The US-based OSD plant at Dayton is expected to commence commercial manufacturing in Q2 of FY26.

The acquisition is progressing well with FTC; expected to close in the first quarter of FY2027.